Acute GVHD (aGVHD) is a major cause of morbidity and mortality in hematopoietic allograft recipients. The best therapy for patients failing to respond, or not tolerating, systemic glucocorticoids remains undefined. We evaluated the efficacy of sirolimus in 34 patients, median age of 49 (23-67) years, with steroid-refractory (n ¼ 31) or steroid-intolerant (n ¼ 3) aGVHD. aGVHD was diagnosed at a median of 34 (7-1042) days post allografting, and confirmed by biopsy in all cases. Initial aGVHD treatment consisted of prednisone up to 2 mg/kg. Sirolimus was initiated at a median of 9 (1-255) days after glucocorticoid initiation. A sirolimus loading dose was administered to 19 (56%) of 34 patients, median 6 (3-8) mg, followed by maintenance of 1-2 mg/day to target therapeutic trough levels between 4 and 12 ng/ml. Overall response rate was 76%. Fifteen (44%) of 34 patients achieved CR, defined as complete resolution of aGVHD sustained for at least 1 month, after sirolimus initiation without additional immunosuppressive agents. CR was achieved in 11 (42%) of 31 steroid-refractory and 2 (67%) of 3 steroid-intolerant patients. Median OS after initiation of sirolimus was 5.6 months, and 1-year OS was 44% (95% CI: 27-60%). Sirolimus is effective in controlling steroid-refractory aGVHD.
Introduction
Acute GVHD (aGVHD) represents a major cause of morbidity and mortality in allogeneic hematopoietic cell transplantation recipients. [1] [2] [3] [4] There is no consensus with regard to the best therapy for patients who fail to respond, or do not tolerate, systemic steroids. Sirolimus (Rapamune, Wyeth, Philadelphia, PA, USA) is an inhibitor of the mammalian target of rapamycin kinase and has been studied for prophylaxis of aGVHD, 5 as a primary aGVHD therapy, 6 as well as in a phase I trial for treatment of steroid-refractory aGVHD. 7 The efficacy of sirolimus as prophylaxis for GVHD has been suggested when combined with cyclosporine or tacrolimus either alone or in combination with methotrexate in patients undergoing matched-related or unrelated donor allografts. 5, 8, 9 Data evaluating the safety of sirolimus as treatment for steroid-refractory aGVHD are limited to a phase I trial of 21 patients treated with 4-5 mg/m 2 /day for 14 days either with, or without, a 15 mg/m 2 loading dose. The toxicity was overwhelming, with severe thrombotic microangiopathy (TMA) and renal failure in 420% of patients, but the efficacy analysis showed an overall response rate of 57% and a CR rate of 24%. 7 Here, we evaluate the efficacy of sirolimus as a salvage therapy in patients with steroid-refractory (n ¼ 31) or steroid-intolerant (n ¼ 3) aGVHD targeting serum serolimus levels between 4 and 12 ng/ml.
Patients and methods
This retrospective study was approved by the Institutional Review Board of the University of South Florida. Between November 2004 and September 2008, 34 consecutive allogeneic hematopoietic cell transplantation recipients received treatment with sirolimus for steroid-refractory aGVHD (n ¼ 31), or steroid-intolerant aGVHD (n ¼ 3). Steroid-refractory was defined by grade progression within 3 days or failure to achieve at least one grade improvement over 5 days after initiation of systemic glucocorticoid therapy, or later grade progression on primary glucocorticoid therapy. Steroid-intolerant cases included those where sirolimus was used with the intention of decreasing the glucocorticoid dose. Initial doses of systemic methylprednisolone or equivalent glucocorticoid ranged from 1 to 2 mg/kg. Data were collected on day of onset of aGVHD and weekly thereafter; organ-specific grade and overall grade were assigned according to the Glucksberg's modified consensus criteria. 10 Included here are both aGVHD occurring within 100 days after transplantation and persistent or late aGVHD occurring more than 100 days post transplantion; in both cases, no features of chronic GVHD (cGVHD) were concurrently present. Duration of steroid exposure and overall duration of immunosuppression, cumulative incidence and severity of cGVHD, 11 CMV reactivation, primary disease relapse, and death are reported. Maximal percent reduction from starting dose of glucocorticoids over 12 weeks after initiation of sirolimus is also reported.
Adverse effects of sirolimus, including maximal decrease in absolute neutrophil count and platelet count within 30 days after initiation of sirolimus, occurrence of TMA (defined by BMT CTN consensus definition), 12 and hyperlipidemia (according to CTC criteria version 3), were also recorded and scored. For cases of ongoing refractory aGVHD, additional therapeutic agents used as salvage therapy after failure of sirolimus were recorded.
Definition of response CR was defined as complete resolution of aGVHD sustained for at least 1 month after initiation of sirolimus alone; partial response was defined as overall improvement of 1 or more grade. Those who had persistent aGVHD after sirolimus requiring additional immunosuppressive therapies were considered unresponsive to sirolimus. Any recurrent aGVHD was recorded until last follow-up or time of death. Cumulative incidence of primary disease relapse, cGVHD, and CMV reactivation was calculated. The Kaplan-Meier method was used to estimate OS, and relapse-free survival. With death or relapse as competing risk events, the cumulative incidence of the following outcomes was calculated: o20 mg prednisone per day, freedom from steroids, and freedom from all immunosuppression.
Therapy for aGVHD
The diagnosis of aGVHD was established at a median of 34 (7-1042) days after transplantation, with an interquartile range of 66 days. One patient developed a syndrome consistent with grade III aGVHD at 1042 days post transplantation without clinical features of chronic GVHD. All cases of aGVHD were confirmed histologically and represented a diverse array of overall onset grade and organ involvement, as shown in Table 1 .
Initial treatment of aGVHD consisted of prednisone at a dose up to 2 mg/kg (62% were treated with a median of 1 mg/kg (range 0.12-1.0), whereas the remainder were treated with a median of 2 mg/kg (range 1.5-2.0)). Sirolimus was initiated at a median of 9 (1-255) days after glucocorticoids. Five patients had received other salvage agents before administration of sirolimus: three had received MMF, and two patients received infliximab. A loading dose of sirolimus was administered to 19 (56%) of 34 patients at a median dose of 6 (range 3-8) mg, whereas the remaining 15 (44%) did not receive a Sirolimus for steroid-refractory aGVHD treatment D Hoda et al loading dose. This was followed by a maintenance dose of 1-2 mg/day adjusted to target therapeutic levels of 4-12 ng/ ml. In all patients represented here, tacrolimus was given concurrently with sirolimus, as all received a tacrolimuscontaining aGVHD prophylaxis regimen and none had stopped tacrolimus by time of aGVHD primary treatment and salvage; the target serum range for tacrolimus was 3-7 ng/ml when given concurrent with sirolimus. Therapeutic levels were achieved in all patients, including those who had gastrointestinal manifestations of aGVHD.
Results

Response to therapy
The overall response rate among all 34 patients was 76%. Fifteen (44%) of the 34 patients achieved a CR and 11 (32%) a partial response after treatment with sirolimus. Weekly overall aGVHD scores after initiation of sirolimus are presented in Figure 1 . Two (67%) of 3 patients with steroid-intolerant aGVHD and 13 (42%) of 31 with steroidresistant GVHD achieved a CR after treatment with sirolimus alone; none of those who achieved CR with sirolimus alone had received other salvage agents before sirolimus. When we assessed response to additional therapies for ongoing refractory aGVHD after failing sirolimus as salvage therapy, we found that a total 22 (65%) of 34 patients ultimately achieved CR by time of last follow-up or death.
Organ-specific CR rates were as follows: skin 4/13, with median time-to-best response of 4 (1-8) weeks; gastrointestinal 12/27, with median time-to-best response 4.5 (1-6) weeks; and liver 2/4, with median time-to-best response 3 (2-4) weeks. CR rates varied according to the overall aGVHD grade at the time of salvage with sirolimus (grade I/II: 9/18; grade III: 4/8; grade IV: 2/8) (P ¼ 0.54). Four (27%) of 15 patients who achieved CR after sirolimus alone experienced recurrent aGVHD at a median of 80 (61-144) days after original episode of aGVHD. Univariate analysis was performed to examine the relationship between all baseline characteristics and the achievement of CR after treatment with sirolimus alone, and none reached statistical significance, including organ involvement, overall grade at time of salvage therapy with sirolimus, time of initiation of sirolimus from steroid initiation, or starting glucocorticoid dose. There was no significant relationship between the administration of a loading dose of sirolimus and complete response to sirolimus.
With a median follow up of 7 (1-49) months, the cumulative incidence of cGVHD in this series was 44%, shown to be mild in 10, moderate in 3, and severe in 2 patients. The cumulative incidence of malignancy recurrence was 15%. CMV reactivation was seen in 7/13 seropositive donor/recipient pairs, 2/3 donor-positive/recipient-negative pairs, 3/9 donor-negative/recipient-positive pairs, and 0/9 seronegative donor and recipient pairs.
Liberation from glucocorticoids
The maximum decrease in steroid dose over 12 weeks from sirolimus initiation was a median of 50% (range 0-100%). With death or relapse as competing risks, the cumulative incidence of reaching o20 mg of prednisone was 41%. In addition, the cumulative incidence of complete cessation of prednisone was 17%. Finally, the cumulative incidence of successfully ceasing all immunosuppressive agents was only 4%.
Toxicities associated with sirolimus
The median (range) percent decreases in absolute neutrophil count and platelets were 57% (0-99%) and 61% (0-94%), respectively, within 30 days of sirolimus initiation. We found the maximal grades of hyperlipidemia after initiation of sirolimus to be as follows per CTC criteria: grade 0 (n ¼ 19), grade 1 (n ¼ 12), grade 2 (n ¼ 3), and grade 3 (n ¼ 0). TMA per BMT CTN criteria occurred in seven (21%) patients: grade 1 in five patients and grade 2 in two patients. TMA was successfully managed with dose reduction (n ¼ 3) or discontinuation (n ¼ 4) of tacrolimus.
Survival
Median OS (Figure 2 ) after initiation of sirolimus was 5.6 months (95% CI: 3.7-not reached), and 1-year OS was 44% (95% CI: 27-60%). Median relapse-free survival was 5.2 months (95% CI: 2.4-not reached). Causes of death Disease remission status at time of allografting was a significant predictor for survival; the hazard ratio for death was 0.18 (95% CI: 0.05-0.63; P ¼ 0.007) for those in remission. Additionally, CR from aGVHD with sirolimus alone was a significant predictor of OS. Although median OS was not reached in those who attained CR with sirolimus alone, median OS for those who did not was 2.9 months (95% CI: 1.4-4.8). Hazard ratio for death in those achieving CR with sirolimus alone was 0.13 (95% CI: 0.04-0.47; P ¼ 0.002). No other baseline characteristics, including organ involvement or grade of aGVHD at time of salvage, were significant predictors of OS in this analysis.
Discussion
Several immunosuppressive agents have been evaluated as secondary treatment for steroid-refractory aGVHD, with limited success. Mycophenolate mofetil has shown modest activity as salvage therapy in patients with steroidrefractory aGVHD. [13] [14] [15] [16] Other studies have shown encouraging responses when using anti-thymocyte globulin early in the course of the disease. 17 Other therapies tested in single-arm studies include infliximab, 18, 19 pentostatin, 20 alemtuzumab, 21 the humanized anti-CD3 antibody visilizumab, 22 denileukin diftitox, 23 and extracorporeal photopheresis 24, 25 among others. Use of ex vivo-expanded mesenchymal stem cells is a promising strategy, showing CR rates of over 50% in patients with steroid-refractory aGVHD. /day (n ¼ 10) for 14 days alone. Only 11 completed the anticipated 14-day course, primarily because of lack of improvement and because of toxicity, including hematologic toxicity and TMA. Despite these limitations, 5 of 21 patients achieved complete resolution, suggesting a potential role for sirolimus in the salvage of steroid-refractory aGVHD. Importantly, our approach differed from Benito et al., as sirolimus was continued at the treating physician's discretion indefinitely, rather than for a fixed duration.
Here, patients with steroid-refractory or -intolerant aGVHD were treated with sirolimus as salvage therapy, and we observed an encouraging CR rate of 44%. There were no significant differences observed in CR across organ distribution or aGVHD severity at the time of salvage. Importantly, therapeutic levels were consistently achieved, and resultant responses were attained in those with gastrointestinal involvement, including advanced grade gastrointestinal involvement and gastrointestinal bleeding. This is important, as sirolimus is only available as an oral formulation and has poor bioavailability. Additionally, in most cases, sirolimus allowed a reduction in glucocorticoid exposure: the cumulative incidence of reaching the endpoints of o20 mg of prednisone, cessation of prednisone, and cessation of all immunosuppressive agents was 41%, 17%, and 4%, respectively. This is particularly important in patients with steroid-refractory aGVHD, as prolonged exposure to high doses of systemic steroids is associated with increased morbidity and mortality. Other toxicities such as TMA and hyperlipidemia were manageable and did not result in associated grade IV toxicities or death.
The majority of patients (62%) described herein were started on p1 (median ¼ 1 (0.12-1.0)) mg/kg of methylprednisolone as the preferred treatment dose, representing a shift in practice favoring use of smaller doses of systemic steroids. Twelve (57%) of 21 patients treated with p1 mg/ kg and 3 (23%) of 13 patients treated with 41 (median ¼ 2 (1.5-2.0)) mg/kg of glucocorticoids achieved CR with sirolimus alone. Odds of CR with sirolimus alone for the group of patients who received p1 mg/kg is 4.44 times the odds for those who received 41 mg/kg (95% CI: 0.94-21.0) (P ¼ 0.055). Although this was an unplanned, retrospective observation, these findings may suggest an increased likelihood of response to sirolimus in patients treated with p1 mg/kg because of difference in the underlying biology of aGVHD syndrome; those who showed progression through 2 mg/kg of glucocorticoids may be less likely to respond to salvage therapies beyond first-line glucocorticoids. However, this is limited by the fact that those with aGVHD refractory to p1 mg/kg may have possibly responded to an escalated dose of glucocorticoids without other salvage agents. A retrospective analysis by Mielcarek et al. 27 on 733 allograft recipients showed that using lower doses of steroids, equivalent to 1 mg/kg, did not compromise GVHD control or mortality but was associated with less toxicity overall. However, the majority of patients evaluated in that study had grades I-II aGVHD (338 (98%) of 347 patients received 1 mg/kg vs 323 (84%) of 386 patients received Sirolimus for steroid-refractory aGVHD treatment D Hoda et al 2 mg/kg), limiting the ability to derive similar conclusions for patients with more advanced GVHD grades. Although our study is limited by its retrospective nature, it shows that sirolimus is an effective option for the treatment of steroid-refractory aGVHD, resulting in improved OS for those who achieve CR of refractory aGVHD with a manageable toxicity profile.
